SCNX (Scienture Holdings) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNX Scienture Holdings Inc SCNX
47 GF Score
Price $0.37
GF Value $0.35
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Scienture Holdings Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

SCNX
47GF Score
Scienture Holdings Inc SCNX
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Scienture Holdings (SCNX) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued. The current stock price of $0.37 is trading 7% above its estimated GF Value™ of $0.35. GuruFocus considers Scienture Holdings to be Fairly Valued.

Key valuation signals for SCNX:

  • Total Noninterest Expense:
  • GF Value™: $0.35 vs. price of $0.37 (7% above fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scienture Holdings Business Description

Other Exchanges 4E4:Germany
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score

Get the complete analysis for SCNX

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price
$0.35
GF Value